Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs

Author(s): Daria Bottai, Agnese Serafini, Alessandro Cascioferro, Roland Brosch, Riccardo Manganelli

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 27 , 2014

Become EABM
Become Reviewer
Call for Editor


The emergence of multi- and extensively-drug resistant strains of Mycobacterium tuberculosis makes the development of novel anti-tubercular compounds and the identification of alternative mycobacterial drugable targets urgent priorities. Recently, type VII secretion systems (T7SS) have been discovered in mycobacteria. The genome of M. tuberculosis encodes 5 of such systems (ESX-1 to - 5), three of which have been characterized and shown to be essential for viability (ESX-3, ESX-5) or virulence (ESX-1, ESX-5). Because of their crucial role in host-pathogen interactions as well as their involvement in basic biological processes of tubercle bacilli, T7SS/ESX represent promising targets for novel anti-tuberculosis drugs. Here, we review the current knowledge of the T7SS/ESX and their impact on M. tuberculosis physiology and virulence. Finally, we discuss the possible approaches to develop T7SS/ESX inhibitors.

Keywords: M. tuberculosis, secretion, virulence, drugs development, tuberculosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 18 November, 2013
Page: [4346 - 4356]
Pages: 11
DOI: 10.2174/1381612819666131118170717
Price: $65

Article Metrics

PDF: 74